The blood–brain barrier shields the central nervous system from harm, but its formidable defenses can also block many promising therapeutics.

A detailed regulatory document that provides evidence that a new drug is safe opens the door to human testing.

Now all researchers interested in developing therapeutics for autism, Parkinson's, or adjacent conditions can request access to the SPARK NS Learning Center.

From accelerated approval to breakthrough therapy designation, regulators have expanded opportunities for getting promising drugs to patients faster.

Michael Rapé, PhD: Targeting Mitochondria to Treat Parkinson’s Disease

PIs in the SPARK NS program reflect on the challenges, expertise, and support needed to move Parkinson’s and autism discoveries toward patients.

GPNMB, encoded by a Parkinson’s disease (PD) risk gene, is secreted by microglia in response to neuronal damage. Microglia-derived GPNMB can enhance uptake of pathological forms of alpha-synuclein—the...

A new therapeutic breakthrough is never guaranteed, but a comprehensive, thoughtful plan can help.

Stories, turning points, and motivations shaping the next generation of therapeutics for Parkinson’s disease.

SPARK NS seeks academic researchers developing autism and Parkinson’s therapeutics. Up to $2M funding plus translational support. Apply by 5 June 2026.